Prostate Cancer Treatment... Targeting Launch Next Year
Dongkook Pharmaceutical announced on the 24th that it has completed a phase 3 clinical trial of Lorelin Depot Injection 3-Month Formulation (DKF-MA102), a long-acting injectable treatment for prostate cancer.
The company aims to finalize the clinical study report within this year, proceed sequentially with marketing authorization, and launch the product next year.
Lorelin Depot Injection contains leuprorelin as its active ingredient and suppresses the secretion of gonadotropins, thereby reducing blood levels of testosterone and estrogen. In addition to prostate cancer, it is used as a treatment for hormone-related diseases such as endometriosis and precocious puberty.
This new 3-month injectable formulation is based on Dongkook Pharmaceutical's microsphere (micro-particle) formulation technology. Currently, there is only one 3-month injectable product of leuprorelin 11.25 mg being sold in the domestic market, and the company expects that once this product is launched, it will be able to expand its market presence. The domestic leuprorelin formulation market is estimated at about 80 billion won.
A Dongkook Pharmaceutical official said, "If the 3-month formulation of Lorelin Depot Injection is launched, we expect it will significantly improve patients' dosing convenience and quality of life."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
